23-Dec-2025
Globe Newswire (Sat, 6-Dec 8:05 AM ET)
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
Globe Newswire (Wed, 26-Nov 7:00 AM ET)
Globe Newswire (Mon, 24-Nov 7:00 AM ET)
Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Globe Newswire (Wed, 5-Nov 7:00 AM ET)
Globe Newswire (Mon, 3-Nov 4:00 PM ET)
Arvinas to Participate in Upcoming Investor Conferences
Globe Newswire (Mon, 3-Nov 7:00 AM ET)
Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025
Globe Newswire (Wed, 29-Oct 7:00 AM ET)
ARV-806 Shows Best-in-Class Potential with 25-Fold Higher Potency in KRAS G12D-Mutated Cancer Models
Market Chameleon (Mon, 27-Oct 3:40 AM ET)
Globe Newswire (Fri, 24-Oct 4:00 PM ET)
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Arvinas trades on the NASDAQ stock market under the symbol ARVN.
As of December 23, 2025, ARVN stock price declined to $12.18 with 579,038 million shares trading.
ARVN has a beta of 1.32, meaning it tends to be more sensitive to market movements. ARVN has a correlation of 0.06 to the broad based SPY ETF.
ARVN has a market cap of $782.25 million. This is considered a Small Cap stock.
Last quarter Arvinas reported $42 million in Revenue and -$.48 earnings per share. This beat revenue expectation by $15 million and exceeded earnings estimates by $.27.
In the last 3 years, ARVN traded as high as $53.08 and as low as $5.90.
The top ETF exchange traded funds that ARVN belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.
ARVN has underperformed the market in the last year with a price return of -34.1% while the SPY ETF gained +17.6%. However, in the short term, ARVN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +61.8% vs +3.5% return in SPY. But in the last 2 weeks, ARVN shares have been beat by the market, returning -8.6% compared to an SPY return of +0.9%.
ARVN support price is $11.91 and resistance is $12.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARVN shares will trade within this expected range on the day.